Denmark · Funded startup

Who invested in Zealand Pharma

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechPharma

Raised 2 months ago

Funding summaryUpdated 26 Oct 2026

$100Mraised across 1 round since 2026, from 1 source

Latest round
Round, $100MAug 2026
Led by
Royalty Pharma
Investors
1 (1 led)
See who backed them

The rounds

  1. Aug 2026
    Round$100M

    Reported by Royalty Pharma

Everyone who backed them

Royalty PharmaGrowth equity1round, led 1

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 3 firms list Zealand Pharma as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

KurmaPartnersVC firmPer its own site
Athyrium Capital ManagementPrivate equityPer its own site
Avoro Capital Advi...Private equityPer its own site

Quick answers about Zealand Pharma

Who invested in Zealand Pharma?

Zealand Pharma's investors include Royalty Pharma. Royalty Pharma led its latest round.

How much has Zealand Pharma raised?

Zealand Pharma has raised $100M across 1 round since 2026.

When did Zealand Pharma last raise?

Zealand Pharma's most recent round was an Undisclosed round of $100M in Aug 2026, led by Royalty Pharma.

What was Zealand Pharma's biggest round?

Its most recent round, $100M in Aug 2026, is also its largest on record.

Who backed Zealand Pharma first?

Zealand Pharma's first round on record, in Aug 2026, was backed by Royalty Pharma.

What stage is Zealand Pharma at?

Zealand Pharma's latest named round is an Undisclosed round, in Aug 2026.

Where is Zealand Pharma based?

Zealand Pharma is based in Denmark.

Who led Zealand Pharma's rounds?

Royalty Pharma led the Undisclosed round in 2026.

Companies like Zealand Pharma

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.